RE-TREATMENT WITH SECOND GENERATION, ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS IN RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA (ACIT001-3)

Registry ID

ACIT001-3

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

THE GOVERNORS OF THE UNIVERSITY OF ALBERTA

Start date

2025-07-11

Last update

2025-06-17

Conditions

• ACUTE LYMPHOBLASTIC LEUKEMIA

Related clinical trials

• A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
• A MODULAR PHASE I/II, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, IMMUNOGENICITY, AND PRELIMINARY EFFICACY OF AZD4512 MONOTHERAPY OR IN COMBINATION WITH ANTICANCER AGENT(S) IN PARTICIPANTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
• A PHASE 1/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF AZD0486 IN ADOLESCENT AND ADULT PARTICIPANTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA
• A RANDOMIZED TRIAL OF LEVOCARNITINE PROPHYLAXIS TO PREVENT ASPARAGINASE-ASSOCIATED HEPATOTOXICITY IN ADOLESCENTS AND YOUNG ADULTS RECEIVING ACUTE LYMPHOBLASTIC LEUKEMIA THERAPY
• A PHASE IB STUDY OF THE PHARMACOKINETICS, SAFETY AND EFFICACY OF ORALLY ADMINISTERED HQP1351 IN SUBJECTS WITH REFRACTORY CHRONIC MYELOID LEUKEMIA (CML) AND ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
• A PHASE 1/2 OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ADMINISTRATION OF SUBCUTANEOUS BLINATUMOMAB FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B ALL

View on source registry